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Invasive candidiasis (IC) has emerged as a main cause of
morbidity and mortality among critically ill patients.
Candida colonization at multiple sites promoted by pro-
longed exposure to antibiotics, intravascular devices for
parenteral nutrition or renal replacement therapy, and
complicated abdominal surgery are associated with the
development of IC [1]. The gastrointestinal tract and en-
dovascular catheters are thus the most common sources of
IC [2].
Early recognition and appropriate management of IC
are crucial for outcome [3, 4]. However, the sensitivity of
conventional blood cultures remains limited. The utility
of fungal blood markers such as beta-(1,3)-D-glucan or
mannan/antimannan and PCR testing for the early diagnosis
of IC needs to be confirmed in the ICU setting [5, 6].
Pending the conclusion on ongoing investigations and on
the role of composite clinical scores which may improve the
prediction of IC, therapeutic decisions remain essentially
based on the clinical risk profile [7]. This approach results
in a low threshold for starting antifungals (prophylactic,
pre-emptive or empirical treatment) and in a high number
needed to treat to target a single IC episode [8, 9].
It has been suggested that the epidemiological shift
from Candida albicans to species intrinsically resistant
(Candida krusei) or with decreased susceptibility to
azoles (Candida glabrata) observed in some institutions
is a consequence of an overuse of antifungals [10, 11].
While the efficacy of fluconazole as first-line therapy of
IC is being challenged, well tolerated but expensive
alternative broad-spectrum antifungal agents are now
available and will be recommended in the updated IDSA
guidelines for the management of IC [11–14]. These new
drugs are expected to impact positively on the outcome of
IC; however, the economical and ecological conse-
quences of their increasing use are difficult to predict
[15, 16]. Despite an improved therapeutic armamenta-
rium, there is thus an urgent need for new management
strategies for better targeting the use of antifungal agents.
This is the aim of the paper published by Pe´rez-Para et al.
[17] in the current issue of the Journal, in which a frequent
not evidence-based trigger for starting antifungal therapy is
challenging. In a retrospective analysis the authors suggest,
in contrast to the common opinion, that a central venous
catheters (CVC) tip culture positive for Candida spp. is not
synonymous of IC or of increased risk for developing IC.
Among 215 non-neutropenic critically ill patients with a
positive CVC culture at a single academic institution, a
subgroup of 58 patients (27%) with negative blood cultures
drawn within 7 days before and 7 days after catheter
removal was analyzed. Twenty patients received antifun-
gals and only one developed IC (i.e., 2% of the cases),
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suggesting that the number needed to treat a single IC
episode would be substantial. Independent predictors of
poor outcome were a McCabe score corresponding to
ultimately fatal underlying disease and the presence of
severe sepsis, septic shock or multiorgan failure. The
authors concluded that antifungal treatment did not impact
on the clinical outcome in these patients [17].
In patients with bloodstream infection removal of the
CVC has been suggested in previous investigations to
accelerate the clearance of bacteremia or fungemia. In
critically ill patients with sepsis and no documented
infectious focus it is common practice to promptly remove
and/or exchange the indwelling intravascular devices. In
the absence of concomitant positive blood cultures, the
clinical signification of a catheter tip culture positive for
Candida spp. remains to be determined [18]. Nevertheless,
in order to avoid acute and late complications of IC, many
clinicians start antifungal therapy in this setting. The study
by Pe´rez-Para et al. suggests that this subgroup of patients
should not receive antifungal therapy.
However, many questions remain unanswered. The
reason for CVC removal and culture are not specified. Did
these patients present a sepsis of unknown origin or was
the device removed for end of use and routinely sent for
culture despite absence of any symptoms and signs of
infection? [18]. The cut-off value of one colony forming
unit used for defining catheter colonization may have
selected a subgroup of patients with an extremely low
level of CVC colonization: whether a higher colony count
is associated with an increased risk of IC remains
unknown. The significance of a positive catheter culture
for Candida spp. in the absence of candidemia and of
clinical signs of infection may differ according to the
presence or absence of a colonization at other sites.
Although the dynamics of colonization assessed semi-
quantitatively by the colonization index has been shown
to predict the risk of IC, this information is lacking in the
present study [8, 9, 12]. Simultaneous sampling of blood
cultures from a catheter line and by peripheral veni-
puncture is recommended. Results of blood cultures
obtained through the colonized device have, however, not
been reported. Whether a positive result or other clinical
characteristics did influence the decision to start an anti-
fungal therapy remains unknown. Further, blood cultures
were drawn within 7 days before or after CVC removal: is
such a large time window reasonable to exclude candi-
demia in a patient with a positive CVC culture? Finally,
one may challenge the decision to a priori exclude from
the analysis the 64 patients with a concomitant candide-
mia, the 44 patients in whom no blood cultures have been
drawn and the 26 children. These selection criteria might
have biased the retrospective assessment of the target
population [17].
Beyond these major limitations, these data suggest that
a catheter tip culture positive for Candida spp. in the
absence of candidemia should not be automatically con-
sidered as an IC or a condition at high risk for developing
IC. This observation suggests a reduction of the undis-
criminated use of antifungal agents in this setting.
However, this conclusion needs to be confirmed in pro-
spective investigations assessing in which subset of
patients with a positive CVC tip culture withholding or de-
escalating antifungals is safe. These should be designed by
defining the underlying conditions (risk factors, coloni-
zation, clinical signs of infection), by standardizing the
diagnostic procedures (CVC cultures, blood cultures) and
by distinguishing the type of intervention (i.e., prophy-
lactic or pre-emptive/empirical antifungal therapy).
References
1. Eggimann P, Garbino J, Pittet D (2003)
Epidemiology of Candida species
infections in critically ill non-
immunosuppressed patient. Lancet
Infect Dis 3:685–702
2. Nucci M, Anaissie E (2001) Revisiting
the source of candidemia: skin or gut?
Clin Infect Dis 33:1959–1967
3. Raad I, Hanna H, Boktour M, Girgawy
E, Danawi H, Mardani M, Kontoyiannis
D, Darouiche R, Hachem R, Bodey GP
(2004) Management of central venous
catheters in patients with cancer and
candidemia. Clin Infect Dis
38:1119–1127
4. Garey KW, Rege M, Pai MP, Mingo
DE, Suda KJ, Turpin RS, Bearden DT
(2006) Time to initiation of fluconazole
therapy impacts mortality in patients
with candidemia: a multi-institutional
study. Clin Infect Dis 43:25–31
5. Prella M, Bille J, Pugnale M, Duvoisin
B, Cavassini M, Calandra T, Marchetti
O (2005) Early diagnosis of invasive
candidiasis with mannan antigenemia
and antimannan antibodies. Diagn
Microbiol Infect Dis 51:95–101
6. Senn L, Robinson JO, Schmidt S,
Knaup M, Asahi N, Satomura S,
Matsuura S, Duvoisin B, Bille J,
Calandra T, Marchetti O (2008) 1, 3-
Beta-D-glucan antigenemia for early
diagnosis of invasive fungal infections
in neutropenic patients with acute
leukemia. Clin Infect Dis 46:878–885
7. Leon C, Ruiz-Santana S, Saavedra P,
Almirante B, Nolla-Salas J, Alvarez-
Lerma F, Garnacho-Montero J, Leo´n
MA, EPCAN Study Group (2006) A
bedside scoring system (‘‘Candida
score’’) for early antifungal treatment in
nonneutropenic critically ill patients
with Candida colonization. Crit Care
Med 34:730–737
8. Eggimann P, Garbino J, Pittet D (2003)
Management of Candida species
infections in critically ill patient. Lancet
Infect Dis 3:772–785
9. Mean M, Marchetti O, Calandra T
(2008) Bench-to-bedside review:
Candida infections in the intensive care
unit. Crit Care 12:204
10. Pfaller MA, Diekema DJ, Gibbs DL
(2007) Results from the ARTEMIS
DISK Global Antifungal Surveillance
study, 1997 to 2005: an 8.5-year
analysis of susceptibilities of Candida
species and other yeast species to
fluconazole and voriconazole
determined by CLSI standardized disk
diffusion testing. J Clin Microbiol
45:1735–1745
11. Brion LP, Uko SE, Goldman DL (2007)
Risk of resistance associated with
fluconazole prophylaxis: systematic
review. J Infect 54:521–529
12. Guery BP, Arendrup MC, Auzinger G,
Azoulay E, Borges Sa´ M, Johnson EM,
Mu¨ller E, Putensen C, Rotstein C,
Sganga G, Venditti M, Zaragoza Crespo
R, Kullberg BJ (2009) Management of
invasive candidiasis and candidemia in
adult non-neutropenic intensive care
unit patients: Part II. Treatment.
Intensive Care Med. doi:10.1007/
s00134-008-1339-6
13. Playford EG, Eggimann P, Calandra T
(2008) Antifungals in the ICU. Curr
Opin Infect Dis 21:610–619
14. Rex JH. http://www.uncedu/*churt/id_
cc_ppts/IDSA_Candidiasis_Rex ppt.
Accessed 9th Jan 2009
15. Forrest GN, Weekes E, Johnson JK
(2008) Increasing incidence of Candida
parapsilosis candidemia with
caspofungin usage. J Infect 56:126–129
16. Johnson E, Espinel-Ingroff A, Szekely
A, Hockey H, Troke P (2008) Activity
of voriconazole, itraconazole,
fluconazole and amphotericin B in vitro
against 1763 yeasts from 472 patients in
the voriconazole phase III clinical
studies. Int J Antimicrob Agents
32:511–514
17. Pe´rez-Parraz A, Munoz P, Guinea J,
Martin-Rabadan P, Guembe M, Bouza
E (2009) Is Candida colonization of
central vascular catheter in non-
candidemic, non-neutropenic patients
an indicator for antifungals? Intensive
Care Med. doi:10.1007/s00134-
009-1431-6
18. Eggimann P (2007) Diagnosis of
intravascular catheter infection. Curr
Opin Infect Dis 20:353–359
